Svetlana Lucas
CIK 1781292 · Chief Business Officer · last filed 2026-08-04
Svetlana Lucas is a Chief Business Officer who has filed 14 SEC Form 4 insider transactions across 5 companies since 2019. The most recent filing, for JSPR, was dated Aug 4, 2026. Across all open-market trades the lifetime net is +$93.6K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $300.6K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
JSPRW price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 250
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| JSPR | Director | — | $0.51 | — | $0 | 1 | 2026-08-04 |
| SCTX | Chief Business Officer | 3,000 | $15.60 | $46.8K | $45.0K | 1 | 2026-07-27 |
| ATYR | Director | — | $0.15 | — | $0 | 1 | 2026-05-13 |
| Jasper Therapeutics, Inc. (JSPRW) Delisted | Director | 20,000 | $0.00 | $4 | $48.6K | 3 | 2025-09-24 |
| LIFE | Director | 6,000 | $42.30 | $253.8K | $0 | 8 | 2025-05-02 |
Recent Filings
14 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-04 | JSPR | Grant (A) | — | $0 | EDGAR |
| 2026-07-27 | SCTX | Mixed | +3,000 | $45.0K | EDGAR |
| 2026-05-13 | ATYR | Grant (A) | — | $0 | EDGAR |
| 2025-09-24 | Jasper Therapeutics, Inc. (JSPRW) Delisted | Buy (P) | +20,000 | $48.6K | EDGAR |
| 2025-07-03 | Jasper Therapeutics, Inc. (JSPRW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-05-02 | LIFE | Grant (A) | — | $0 | EDGAR |
| 2024-06-20 | Jasper Therapeutics, Inc. (JSPRW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-05-23 | LIFE | Grant (A) | — | $0 | EDGAR |
| 2023-05-19 | LIFE | Grant (A) | — | $0 | EDGAR |
| 2023-04-28 | LIFE | Exer (M) | +6,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.